Abstract
Keratinization defects can be very severe and disfiguring diseases. The development of retinoids such as etretinate has provided us with an effective symptomatic form of oral therapy for these skin conditions. Based on our own experience, we briefly outline the therapeutic potential of etretinate in various keratinization defects (lamellar ichthyosis, Netherton syndrome, Sjögren-Larsson syndrome, mal de Meleda and juvenile pityriasis rubra pilaris). The toxicology of etretinate is reviewed with special regard to the treatment of children. Bone changes such as premature closure of the growth line or other unacceptable side-effects have so far not been observed. Guidelines for patient selection and for the safe treatment of children are given.
Similar content being viewed by others
References
Bauer EA, Seltzner JL, Eisen AZ (1983) Retinoic acid inhibition of collagenase and gelatinase expression in human skin fibroblast cultures. Evidence for a dual mechanism. J Invest Dermatol 81:162–169
Blanchet-Bardon C, Anton-Lamprecht I, Schnyder UW (1977) Erythrodermie congénitale ichtyosiforme bulleuse. Contrôle ultrastructural du traitement par l'éther éthylique d'un dérivé aromatique de l'acide rétinoique. Ann Dermatol Venercol 104: 648–653
Bravo-Piris J, Aparicio M, Moran M, Armijo M (1983) Papillon-Lefèvre syndrome. Report of a case treated with oral retinoid Ro 10-9359. Dermatologica 166:97–103
DiGiovanna JJ, Peck GL (1983) Oral synthetic retinoid treatment in children. Pediatr Dermatol 1:77–88
Ellis CN, Madison KC, Pennes DR, Martel W, Voorhees JJ (1984) Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol 10:1024–1029
Fleissner J, Happle R (1981) Etretinate in the treatment of juvenile pityriasis rubra pilaris. Arch Dermatol 117:749–750
Frenk E (1981) Traitement oral de l'ichtyose lamellaire (erythrodermie ichtyosiforme congénitale non bulleuse) avec un rétinoide aromatique. Etude clinique, microscopique optique et électronique d'un essai thérapeutique de plus de 2 ans. Dermatologica 162:91–103
Gollnick H, Luley C, Schwartzkopff W, Orfanos CE (1982) Veränderungen von Serumlipidfraktionen als Nebenwirkung oraler Retinoide. Z Hautkr 57:1255–1267
Happle R, Niedworok A (1981) Cytogenetic studies in patients treated with oral retinoid Ro 10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 61–65
Happle R, Traupe H (1984) Etretinat bei Genodermatosen und verschiedenen entzündlichen Hautkrankheiten. In: Bauer R, Gollnick H (eds) Retinoide in der Praxis. Grosse, Berlin, pp 35–49
Happle R, Traupe H, Bounameaux Y, Fisch T (1984) Teratogene Wirkung von Etretinat beim Menschen. Dtsch Med Wochenschr 109:1476–1480
Hintner H, Jaschke E, Fritsch P (1980) Netherton-Syndrom: Abwehrschwäche, generalisierte Verrukose und Karzinogenese. Hautarzt 31:428–432
Hummler H, Schüpbach ME (1981) Studies in reproductive toxicology and mutagenicity with Ro 10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 49–59
Jagell S, Lidén S (1982) Treatment of the ichthyosis of the Sjögren-Larsson syndrome with etretinate (Tigason). Acta Dermatovenereol 63:89–91
Miescher G (1954) Behandlung der Ichthyosis mit Vitamin A. Dermatologica 108:300–303
Milstone LM, McGuire J, Ablow RC (1982) Premature epiphyseal closure in a child receiving oral 13-cis-retinoic acid. J Am Acad Dermatol 7:663–666
Obe G, Tsambaos D (1981) Chromosomal analysis in patients treated with the oral aromatic retinoid Ro 10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 67–70
Orfanos CE, Mahrle G, Goerz G, Happle R, Hofbauer M, Landes E, Schimpf A (1979) Laboratory investigations in patients with generalized psoriasis under oral retinoid treatment. A multi-center study of computerized data. Dermatologica 159:62–70
Paravicini U (1981) Pharmacokinetics and metabolism of oral aromatic retinoids. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 13–20
Pehamberger H, Esca SA, Holubar K (1979) Behandlung hyperkeratotischer Dermatosen mit einem oralen, aromatischen Retinoid (Ro 10-9359). Z Hautkr 55:68–78
Pittsley RA, Yoder FA (1983) Retinoid hyperostosis. Skeletal toxicity associated with long-term administration of 13-cis retinoic acid for refractory ichthyosis. New Engl J Med 308:1012–1014
Randazzo SD, Presti VL, Caruso A (1981) A proposal for computing the dosage of the aromatic retinoid Ro 10-9359 in relation to skin surface. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 371–374
Schimpf A (1976) Zur systemischen Anwendung eines aromatischem Vitamin-A-Säure-Derivates (Ro 10-9359) bei Psoriasis und Keratosen. Z Hautkr 51:265–274
Schnyder UW, Vogel A (1980) Zur Behandlung der Erythrodermia congenitalis ichthyosiformis bullosa mit aromatischen Retinoiden. Aktuel Dermatol 6:133–136
Schroeff van der JG, Suurmond D (1981) Treatment of erythrokeratodermia variabilis with oral retinoid (Ro 10-9359). In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 295–301
Stüttgen G (1962) Zur Lokalbehandlung von Keratosen mit Vitamin A-Säure. Dermatologica 124:65–80
Tamayo L, Ruiz-Maldonado R (1981) Long-term follow-up of 30 children under oral retinoid Ro 10-9359. In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 287–294
Teelmann K (1981) Experimental toxicology of the aromatic retinoid Ro 10-9359 (etretinate). In: Orfanos CE, Braun-Falco O, Farber EM, Grupper Ch, Polano MK, Schuppli R (eds) Retinoids. Advances in basic research and therapy. Springer, Berlin, pp 41–47
Van der Rhee HJ, van Gelderen HH, Polano MK (1980) Is the use of Ro 10-9359 (Tigason) in children justified? Acta Dermatovenereol 60:274–275
Wehrmann W, Traupe H, Happle R (1984) Papillon-Lefèvre-Syndrom (Keratosis palmoplantaris mit Periodontopathie): Behandlung mit Etretinat. Hautarzt 35: in press
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. W. Lenz on the occasion of his 65th birthday
Rights and permissions
About this article
Cite this article
Traupe, H., Happle, R. Etretinate therapy in children with severe keratinization defects. Eur J Pediatr 143, 166–169 (1985). https://doi.org/10.1007/BF00442128
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00442128